Advancing Innovation on Rare Disease Therapies
Department of Health and Human Services (HHS) · February 23, 2026
HHS and FDA announced draft guidance establishing a "plausible mechanism" pathway to speed approval of individualized therapies for rare and ultra‑rare genetic diseases, highlighted by the case of baby “KJ.” Officials described how the framework would let well‑controlled investigations and real‑world evidence support approvals, and scientists, families, and reporters discussed implementation and oversight.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.